2017
DOI: 10.3390/biomedicines5030056
|View full text |Cite
|
Sign up to set email alerts
|

CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases

Abstract: To date, no curative therapy is available for the treatment of most chronic inflammatory diseases such as atopic dermatitis, rheumatoid arthritis, or autoimmune disorders. Current treatments require a lifetime supply for patients to alleviate clinical symptoms and are unable to stop the course of disease. In contrast, a new series of immunotherapeutic agents targeting the Fc γ receptor I (CD64) have emerged and demonstrated significant clinical potential to actually resolving chronic inflammation driven by M1-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
59
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 74 publications
(62 citation statements)
references
References 92 publications
(113 reference statements)
1
59
0
1
Order By: Relevance
“…N.D. Not determined. macrophages (10)(11)(12). The TLR2 and TLR4 pattern recognition marker receptors are more highly expressed on BMDMs (Figure 3B and p value list).…”
Section: M1 Markersmentioning
confidence: 94%
“…N.D. Not determined. macrophages (10)(11)(12). The TLR2 and TLR4 pattern recognition marker receptors are more highly expressed on BMDMs (Figure 3B and p value list).…”
Section: M1 Markersmentioning
confidence: 94%
“…Currently, there are new and interesting strategies to change the M1/M2 ratio using different agents. For example, Fc γ RI receptor (CD64), which is up‐regulated in macrophages from chronic inflammation sites was recently targeted with monoclonal antibodies, demonstrating a clinical potential . Taking into account the importance of a correctly balanced M1/M2 ratio in cancer and several autoimmune diseases, new therapies seek to selectively mark and deplete specific macrophage subpopulations.…”
Section: Future Perspectivesmentioning
confidence: 99%
“…Activated monocytes recruited into the site of inflammation undergo monocyte‐to‐macrophage differentiation; nevertheless, there are no definite and distinctive markers that can be used for differential discrimination of these two cell types . Certain genes such as MERTK, CD64, AXL and TYRO3 have been acknowledged to be macrophage specific; low‐level expression of macrophage‐related markers is generally observed in monocytes as well . Expression of these genes is increased in response to inflammatory factors .…”
Section: Discussionmentioning
confidence: 99%